查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495979

全球甲狀腺功能檢測市場 - 2024 年至 2029 年預測

Global Thyroid Function Test Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

甲狀腺功能檢測市場預計到2029年將達到2,414,733,000美元，複合年成長率為5.40%。 2022年市場規模為1,671,171,000美元。

人體的甲狀腺會分泌重要的激素，大大影響人體的生長、發育和正常健康。荷爾蒙分泌的增加或減少會導致健康狀況。因此，診斷和管理對於檢測人體內的甲狀腺激素至關重要。

預測期內推動甲狀腺功能檢測市場的關鍵原因是甲狀腺激素日益失衡及其對健康和身體的不利影響。健康意識的提高和醫療保健支出也正在擴大市場範圍。此外，增加對醫療領域的投資以及鼓勵早期發現疾病並及時用藥以增加生存機會預計將支持市場成長。

市場促進因素：

  • 甲狀腺激素功能障礙的發生頻率不斷增加，推動了定期監測甲狀腺功能的需求，並推動了市場的成長。

甲狀腺激素功能障礙是預計在預測期內推動甲狀腺功能測試市場需求的另一個關鍵因素。透過控制燃燒卡路里的能力，甲狀腺激素會影響身體的新陳代謝。當甲狀腺激素水平過高或過低時，甲狀腺激素會改變身體形狀，分別使人變瘦或變胖。由於生活方式的複雜性，甲狀腺激素問題的案例數量不斷增加，預計將促使定期檢查，以獲得更好的醫療照護。

據美國甲狀腺協會稱，超過 12% 的美國一生中至少患有一次甲狀腺功能障礙。超過 2000 萬人患有甲狀腺問題，其中 60% 的人不知道自己的病情。身體意識、令人信服的激勵措施以及持續、及時的身體檢查的機構後續行動預計將在未來推動一個巨大的表面市場。

  • 肥胖症的日益普及正在引起嚴重關注，預計將為甲狀腺功能檢測行業提供巨大的市場前景。

導致這現象顯著成長的另一個因素是世界人口日益肥胖。世界衛生組織 (WHO) 表示，過去 40 年來，肥胖率增加了兩倍。因此，到 2022 年，將有 25 億成年人超重，8.9 億人患有肥胖症。此外，到 2022 年，將有 3,700 萬名 5 歲以下兒童和 3.9 億 5 歲至 19 歲男孩和女孩超重或肥胖。

肥胖率的穩定上升引起了嚴重關注，甲狀腺激素檢測預計會增加，以實現更好的收益和監管。此外，甲狀腺癌等甲狀腺相關疾病的增加預計將在預測期內推動市場。

  • 甲狀腺癌發病率的上升預計將推動市場擴張。

促進甲狀腺功能檢測的因素之一是甲狀腺癌病例的增加。值得注意。甲狀腺疾病的早期診斷是必要的，接受治療時定期監測也很重要。此外，甲狀腺癌的特殊病例增加了對甲狀腺功能檢查的需求。此外，技術進步和世界人口老化可能會進一步增加市場需求。甲狀腺癌一詞是指異常細胞從正常甲狀腺出現並生長成腫瘤的過程。

根據Cancer.net報道，美國新增一例甲狀腺癌病例。此外，在美國，女性病例數每年以 2% 的速度增加。日益增加的癌症威脅可能為甲狀腺功能測試提供一個穩定的市場。

市場限制因素：

  • 有關甲狀腺功能測試的資訊有限可能會限制甲狀腺功能測試市場的成長。

每次甲狀腺功能測試的主要障礙之一是資訊有限或無法知道測試的陽性結果。根據 ATA資料，由於對甲狀腺領域缺乏認知或興趣，60% 的美國人不知道自己的甲狀腺狀況。

  • 檢測成本的增加可能會阻礙甲狀腺功能檢測市場的成長。

雖然常見的甲狀腺功能測試是可以負擔的，但基因測試和放射性碘攝取掃描等更複雜的測試的費用可能會很昂貴。這可能會限制某些特定患者的機會。

主要進展：

  • 2023 年 2 月 - Parkway Laboratories 的新測試資料「妊娠期甲狀腺篩檢」（代碼：TSP）已新增至產品組合。
  • 2023 年 1 月 - Cipla 推出 Cippoint。經過 CE IVD 認證的 POCT 設備為醫療專業人員提供了一種針對許多非傳染性疾病和感染疾病的便捷的就地檢驗設備。它有心臟、糖尿病、不孕症、甲狀腺功能、發炎、代謝標記、凝血標記等多種參數。 Cipla 是印度開發的診斷工具，透過以合理的價格提供使用螢光的準確測試而贏得了信任。自動化系統（Cippoint）為醫療專業人員提供即時結果（2-15 分鐘）並簡化臨床決策流程。
  • 2022 年 10 月 - 一項 Frontier 研究發現，女性肥胖時 TSH 水平會升高，而瘦素水平是甲狀腺功能參數的關鍵代謝決定因素。在一大群肥胖的甲狀腺功能減退患者中，不同 BMI 範圍內的 TSH 和 fT4 水平模式表明，下丘腦-垂體-甲狀腺軸與體重之間存在多效性關聯。
  • 2022 年 1 月 - Quest Diagnostics 推出 QuestDirect(TM)，這是一項針對成人健康管理的線上預防性健康服務。它包括診斷工具、重要資訊篩檢和健康風險評估。該服務包括診斷工具、生物識別篩檢和健康風險評估，定位為健康教育報告、健康提示以及與醫生一對一的虛擬諮詢。創建該服務的目的是讓用戶能夠存取個人健康資訊和預防保健，並且可以根據每位客戶的繁忙日程安排在方便的時間。

主要市場區隔：

按類型

  • 甲狀腺刺激素測試
  • T4測試
  • T3測試
  • 其他

按指示

  • 甲狀腺機能低下症
  • 甲狀腺功能亢進症
  • 甲狀腺癌
  • 其他

按最終用戶

  • 醫院和診所
  • 診斷中心
  • 其他

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 其他
  • 中東/非洲中東/非洲
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章甲狀腺功能測試的全球市場：按類型

  • 介紹
  • 甲狀腺刺激素測試
  • T4測試
  • T3測試
  • 其他

第6章 甲狀腺功能檢測的全球市場：依適應症分類

  • 介紹
  • 甲狀腺機能低下症
  • 甲狀腺功能亢進症
  • 甲狀腺癌
  • 其他

第7章甲狀腺功能測試的全球市場：依最終用戶分類

  • 介紹
  • 醫院和診所
  • 診斷中心
  • 其他

第8章甲狀腺功能測試的全球市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Abbott
  • Randox Laboratories Ltd
  • bioMerieux SA
  • Thermo Fisher
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers
  • Qualigen Inc.
  • Beckman Coulter, Inc.
  • Quidel Corporation
簡介目錄
Product Code: KSI061611918

The global thyroid function test market is expected to reach a value of US$2,414.733 million by 2029, growing at a CAGR of 5.40%. It was valued at US$1,671.171 million in 2022.

The thyroid gland in the human body secretes important hormones that are great determinants of the human body's growth, development, and proper health. Any increased or decreased production of the hormone can cause a disease condition. Therefore, diagnosis and management are essential in inspecting the thyroid hormones in the human body.

The prime reason driving the market for thyroid function tests during the forecasted period is the rising thyroid hormone imbalance and its adverse effect on health and the body. Surging health consciousness and healthcare expenditure also increase the scope of the market. Furthermore, increasing investment in the healthcare sector and encouraging early detection of disease for timely medication for better chances of survival are projected to support the market growth.

Market Drivers:

  • The Growing frequency of thyroid hormone dysfunction has promoted the need for regular monitoring of thyroid function is driving the market growth.

Thyroid hormone dysfunction is another key factor anticipated to fuel the market demand for thyroid function tests in the projected time frame. By controlling the calorie-burning capability, the thyroid hormone influences the metabolism of the body. It alters the shape of the body when its levels are too high or too low, making a person lean or fat, respectively. Increasing instances of thyroid hormone issues owing to lifestyle complexities are expected to encourage periodic testing for better healthcare.

According to the American Thyroid Association, in the US, over 12% of the population suffer from thyroid malfunction at least once in their lives. More than 20 million people have thyroid issues, and 60% are unaware of their states. Awareness in terms of the body and persuasive motivation and follow from agencies for consistent timely body checks are anticipated to propel the substantial apparent market in the future.

  • Rising obesity has raised serious concerns, which are expected to provide significant market prospects for the thyroid function test industry.

Another factor that will contribute significantly to the tremendous growth is the increasing obesity in the worldwide population. The World Health Organization figures out that the overweight rate has tripled in the last 40 years. Consequently, in 2022 the number of overweight adults was 2.5 billion, and 890 million were living with obesity. Moreover, in 2022, 37 million children less than five years old and also 390 million boys and girls between the ages of 5 and 19 years old were overweight or obese.

The robust growing obesity rates have raised serious concerns, which are anticipated to increase thyroid hormone testing for better monetization and regulation. In addition, the increased number of diseases associated with the thyroid such as thyroidal cancer is expected to drive the market within the forecasted period.

  • The rising incidence of thyroid cancer is projected to drive market expansion.

One of the drivers of thyroid function tests includes the growth of thyroid cancer cases. Notably. Thyroid disorders require early diagnosis, while regular monitoring is essential when seeking treatment. In addition, due to exceptional cases of cancer of the thyroid glands the demand for testing of thyroid function is increasing. Also, technological improvements and an aging global population may further increase market demand. The term thyroid cancer refers to the process by which abnormal cells emerge from a normal thyroid gland and the growth of tumors.

According to Cancer.net, the United States of America recorded new cases of thyroid cancer. Furthermore, according to the report, the US has been reporting an increasing number of women cases at a rate of 2% annually. The increasing cancer threat will provide a stable market for thyroid function tests.

Market Restraint:

  • Limited information about thyroid function tests could curb the thyroid function test market growth.

The one of the main obstacles with respective thyroid function tests is limited information or not being able to know the positive output from the test. Data from ATA states that 60% of Americans are unaware of their thyroid condition owing to a lack of awareness and interest in the sector, which reduces potential patient tests and hence hinders' market growth.

  • Increased cost for testing can hinder the thyroid function test market growth

While the price of the general tests of thyroid function is affordable, the cost of the more complex tests like genetic testing and radioactive iodine uptake scans may be high. This might lead to the restriction of opportunities for some particular patients.

Key Developments:

  • February 2023- Thyroid Screen in Pregnancy (code: TSP), a new test profile from Parkway Laboratories, added to the portfolio. With a trimester-specific reference period, the new test profile's components are identical to those of the thyroid screen basic profile.
  • January 2023- Cipla launched Cippoint, a CE IVD-accredited POCT device that provides healthcare professionals with a handy point-of-care testing device for many non-contagious diseases and infections. It has many parameters to rule the cardiac, diabetes, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. Cipla, developed in India, is a diagnostic tool that is trusted for its precise tests at a reasonable cost utilizing the immunofluorescence technique. Its automated system ( Cippoint ) provides an immediate result for Healthcare professionals (2-15 minutes) and smooths the way of clinical decision-making process. The network server is optimized to cater to regions with low connections such as rural, mobile, and remote areas.
  • October 2022- Frontier study found that TSH levels increase with obesity in females, with leptin levels being the main metabolic determinant of thyroid function parameters. The pattern of TSH and fT4 levels across different BMI ranges in a large cohort of euthyroid patients with obesity suggests a multifold association between the hypothalamic-pituitary-thyroid axis and body weight. However, the potential mechanisms are incompletely understood, and the small proportion of individuals with obesity in published cohort studies provide limited insights into metabolic correlates of thyroid function in obesity.
  • January 2022- Quest Diagnostics began an online preventive care service called QuestDirect(TM) in collaboration with adults as a way for them to take over their health. The service comprises diagnostic tools, biometric screening, and health risk assessment. It, too, ranks as an educational report on health, including some health tips, and puts forward a one-on-one virtual consultation with a physician. This service is created to ensure users have access to personal health information and preventive care that can be scheduled at a convenient time for each client considering their busy schedules.

Key Market Segments:

By Type

  • Thyroid Stimulating Hormone Test
  • T4 Tests
  • T3 Tests
  • Others

By Indication

  • Hypothyroidism
  • Hyperthyroidism
  • Thyroid Cancer
  • Others

By End Users

  • Hospitals and clinics
  • Diagnostic centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL THYROID FUNCTION TEST MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Thyroid Stimulating Hormone Test
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. T4 Tests
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. T3 Tests
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL THYROID FUNCTION TEST MARKET BY INDICATION

  • 6.1. Introduction
  • 6.2. Hypothyroidism
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Hyperthyroidism
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Thyroid Cancer
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL THYROID FUNCTION TEST MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Others
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL THYROID FUNCTION TEST MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Indication
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Indication
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. Spain
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. France
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Indication
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. UAE
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Saudi Arabia
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Indication
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott
  • 10.2. Randox Laboratories Ltd
  • 10.3. bioMerieux SA
  • 10.4. Thermo Fisher
  • 10.5. DiaSorin S.p.A.
  • 10.6. F. Hoffmann-La Roche Ltd.
  • 10.7. Siemens Healthineers
  • 10.8. Qualigen Inc.
  • 10.9. Beckman Coulter, Inc.
  • 10.10. Quidel Corporation